Hospital
Baraga County Memorial Hospital
Baraga County Memorial Hospital was paid $1.87M by Medicaid between Jan 2018 and Dec 2024, across 66 billing codes. Its largest line is 99284, emergency room visit (serious) — 29% of everything it billed.
33Billing provider infoBARAGA COUNTY MEMORIAL HOSPITAL
LANSE, MI 49946
LANSE, MI 49946
33aNPI1558479824assigned 08/28/2006
33bProvider typeCritical Access Hospital
28Total paid$1.87M
24GClaims57,676
24DCodes billed66
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Michigan
Rank by total paid#23 of 31
Median peer was paid$6.03M
This provider vs. median0.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,925 | $161K | |
| 2019 | 7,110 | $145K | |
| 2020 | 6,516 | $187K | |
| 2021 | 8,395 | $330K | |
| 2022 | 9,077 | $336K | |
| 2023 | 9,941 | $362K | |
| 2024incomplete | 8,712 | $349K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 29% | 2,182 | 1,929 | $540K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 2,793 | 2,646 | $428K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 559 | 508 | $271K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 8.2% | 4,012 | 955 | $153K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.3% | 578 | 513 | $80K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.6% | 674 | 656 | $67K |
| 87631 | 3.1% | 1,212 | 1,167 | $57K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.5% | 826 | 785 | $29K |
| 36415 | Collection of venous blood by venipuncture | 1.4% | 11,919 | 8,284 | $26K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.1% | 970 | 888 | $21K |
| 80053 | Comprehensive metabolic panel | 1.0% | 5,735 | 5,046 | $20K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 428 | 415 | $18K |
54 more codes
| 71045 | Radiologic examination, chest; single view | <1% | 282 | $18K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,148 | $17K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,179 | $16K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 97 | $15K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,554 | $14K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 306 | $14K |
| 80061 | Lipid panel | <1% | 1,235 | $12K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 152 | $11K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 309 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 919 | $5K |
| 0012A | <1% | 97 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 988 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 681 | $3K |
| 0011A | <1% | 97 | $3K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 60 | $3K |
| 0013A | <1% | 48 | $2K | |
| 84439 | <1% | 371 | $2K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 15 | $2K |
| 81001 | <1% | 2,454 | $2K | |
| 87077 | <1% | 387 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 360 | $1K |
| 94762 | <1% | 29 | $804.48 | |
| 74019 | <1% | 14 | $773.10 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12 | $772.66 |
| 0001A | <1% | 19 | $719.15 | |
| 87081 | <1% | 183 | $677.90 | |
| 87181 | <1% | 290 | $661.35 | |
| 0003A | <1% | 13 | $492.05 | |
| 0002A | <1% | 13 | $492.05 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 67 | $467.12 |
| 83735 | <1% | 450 | $457.00 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 25 | $414.46 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 14 | $388.64 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 14 | $388.64 |
| 87400 | <1% | 62 | $233.60 | |
| 85610 | <1% | 284 | $216.29 | |
| 82728 | <1% | 24 | $207.35 | |
| 83690 | <1% | 459 | $191.96 | |
| 82607 | <1% | 12 | $66.78 | |
| 87070 | <1% | 12 | $58.50 | |
| 86140 | <1% | 36 | $57.30 | |
| 85027 | <1% | 36 | $39.48 | |
| 85730 | <1% | 123 | $27.73 | |
| 85651 | <1% | 13 | $27.04 | |
| 83605 | <1% | 251 | $26.41 | |
| 85007 | <1% | 39 | $23.68 | |
| 94760 | <1% | 654 | $22.75 | |
| 84703 | <1% | 63 | $12.00 | |
| 81025 | <1% | 12 | $6.81 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 849 | $0.00 |
| 94761 | 0% | 2,143 | $0.00 | |
| 84484 | 0% | 265 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 249 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 320 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHALE, MARQUERITE (CEO)